Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Deproteinized bovine bone mineral (DBBM) is a xenogenic bone substitute material derived from bovine bone through a process that removes all organic components, leaving a natural hydroxyapatite structure. This material serves as an osteoconductive scaffold, providing a framework for the migration of osteogenic cells and the deposition of new bone. In the specific clinical trial conducted by Cairo University, this graft is utilized for sinus floor elevation in patients with an atrophic posterior maxilla to increase bone height and quality prior to dental implant placement. It is evaluated both as a standalone graft and as a carrier for bone marrow aspirate concentrate (BMAC) to enhance regenerative outcomes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on deproteinized bovine bone mineral.